# Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency

> **NCT02112994** · PHASE2 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 31 (actual)

## Conditions studied

- Lysosomal Acid Lipase Deficiency

## Interventions

- **DRUG:** Sebelipase Alfa

## Key facts

- **NCT ID:** NCT02112994
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06-24
- **Primary completion:** 2017-12-28
- **Final completion:** 2017-12-28
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2019-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02112994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02112994, "Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02112994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*